Kulveer S. Mankia

Leeds, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Risk prediction rules in individuals at risk of rheumatoid arthritis: systematic review and validation using the APIPPRA cohort.

Risk prediction rules in individuals at risk of rheumatoid arthritis: systematic review and validation using the APIPPRA cohort.

Journal: EULAR rheumatology open

Published: September 01, 2026

Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8.

Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8.

Journal: Annals of the rheumatic diseases

Published: July 25, 2026

Time to rethink the treatment of palindromic rheumatism.

Time to rethink the treatment of palindromic rheumatism.

Journal: Nature reviews. Rheumatology

Published: July 01, 2026

Association between joint tenderness, patient-reported joint pain and ultrasound abnormalities in anti-CCP positive individuals at risk of rheumatoid arthritis: a cross-sectional study from a Leeds (UK) cohort.

Association between joint tenderness, patient-reported joint pain and ultrasound abnormalities in anti-CCP positive individuals at risk of rheumatoid arthritis: a cross-sectional study from a Leeds (UK) cohort.

Journal: BMJ open

Published: June 04, 2026

High-sensitivity flow cytometry in rheumatoid arthritis shows that early B-cell subset depletion is linked to 5-year rituximab response, while failure to deplete B cells occurs early in subsequent poly-refractory disease.

High-sensitivity flow cytometry in rheumatoid arthritis shows that early B-cell subset depletion is linked to 5-year rituximab response, while failure to deplete B cells occurs early in subsequent poly-refractory disease.

Journal: Annals of the rheumatic diseases

Published: April 10, 2026

Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

Two patterns of sacroiliac joint bone marrow oedema are apparent in AxSpA determined by HLA-B27 status, body mass index or psoriasis.

Journal: Joint bone spine

Published: March 28, 2026

Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis.

Two Patterns of Sacroiliac Joint Bone Marrow Oedema are apparent in AxSpA Determined by HLA-B27 Status, Body Mass Index or Psoriasis.

Journal: Joint bone spine

Published: March 28, 2026

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

Pragmatic, open-label, multicentre, randomised controlled trial to guide initial therapy for immune checkpoint inhibitor-induced inflammatory arthritis comparing standard of care (prednisolone) to adalimumab without glucocorticoids: REACT trial protocol.

Journal: BMJ open

Published: March 03, 2026

T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.

T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.

Journal: Rheumatology (Oxford, England)

Published: February 11, 2026

T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.

T-cell subset biomarkers across the rheumatoid arthritis disease continuum: from clinical utility to adoption in daily practice.

Journal: Rheumatology (Oxford, England)

Published: February 11, 2026

Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials.

Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trials.

Journal: BMJ open

Published: December 15, 2025

Perioperative biologic use and postoperative outcomes in patients with inflammatory arthritis: a systematic review.

Perioperative biologic use and postoperative outcomes in patients with inflammatory arthritis: a systematic review.

Journal: BMC rheumatology

Published: December 11, 2025

Showing 1-12 of 101

Last Updated: 09/26/2026